AliveDx announces US FDA 510(k) submission for MosaiQ AiPlex® Celiac Disease (CD) multiplex microarray

– The MosaiQ AiPlex CD is designed to improve the accuracy and speed of celiac disease diagnosis while simplifying laboratory workflows EYSINS, Switzerland, Feb. 10, 2025 /PRNewswire/ — AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex® Celiac Disease (CD) microarray. The MosaiQ AiPlex CD multiplex […] L'articolo AliveDx announces US FDA 510(k) submission for MosaiQ AiPlex® Celiac Disease (CD) multiplex microarray proviene da La Ragione.

CONTINUA A LEGGERE